Back to Agenda
Transforming Obesity Patient Care: Past, Present, and Future Innovation in the Age of GLP-1 Therapies
Session Chair(s)
Maria Vassileva, PHD
Chief Science and Regulatory Officer
DIA, United States
This plenary session will bring together first-hand perspectives from academic and pharmaceutical experts involved in the development of the GLP1 therapies that first achieved regulatory approval for the treatment of obesity. Speakers will reflect on the scientific and clinical journey that enabled these breakthroughs, while examining how innovation in this space continues to evolve. The session will also address the persistent access gap facing patients worldwide and explore how global companies are working closely with regulators to expand access in a sustainable and equitable manner. Key health policy implications will be discussed, setting the stage for subsequent sessions within the new Chronic Disease and Obesity Pathway.
Learning Objective : Analyze the key scientific and clinical milestones that led to the first regulatory approvals of GLP-1 therapies for obesity using expert perspectives; Assess how innovation in GLP-1 therapies is evolving and consider its impact on future obesity and chronic disease treatment; Examine global access gaps to obesity therapies and identify policy and regulatory strategies to expand equitable and sustainable patient access.
Speaker(s)
Panelist
W. Scott Butsch
Novo Nordisk, Denmark
Internation Medical Vice President - Obesity
Panelist
Brad Jordan, PHD
Eli Lilly and Company, United States
Associate Vice President, Regulatory Policy and Strategy
Have an account?